Close Menu

NEW YORK – Salarius Pharmaceuticals announced it is expanding an ongoing Phase I/II trial of seclidemstat in Ewing sarcoma to include patients with other types of sarcomas with translocations involving the FET family of proteins.

Ewing sarcoma is a bone or soft tissue tumor that mainly occurs in children and young adults, and is caused by a chromosomal translocation that fuses a FET family protein (encoded by FUS, EWSR1 and TAF15 genes) with an ETS family protein, resulting in an altered transcription factor.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.